drugset / Trial / NCT00207974

Pharmacokinetic Study of Marine Active in Health Men

NCT00207974 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Hyperuricemia is often associated with metabolic syndrome, which is a known precursor of atherosclerosis. The Yaizu Suisankagaku Industry Company have developed industrial production, named Marine Active. Human clinical trials showed reduction of creatine phosphokinase activity and sero-uric acid. Randomize, double blind clinical trial is entrust to our hospital. This study design is blood sampling from the health men who take 1 gm of marine active to analyse the pharmacokinetics of anserine.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Marine Active Unknown 1 g —

Indications

No indication recorded.